Researchers at New Haven, Conn.-based Yale University analyzed about 15,000 electronic health records of patients who received opioids from the Veterans Administration between 2000 and 2010. The researchers reviewed patients screened for illicit drug use after starting opioids, which is a procedure recommended by the CDC. Researchers also looked to see if those same patients tested positive for marijuana or cocaine use.
The research team found few patients prescribed opioids tested positive for illicit drug use, but black patients were twice as likely as white patients to undergo the testing one, three and six months after starting opioid therapy.
When white patients tested positive for either marijuana or cocaine, about 90 percent continued to receive their opioid prescriptions. However, black patients were more likely to have their opioid treatment discontinued after testing positive.
“If they were black and tested positive for marijuana, they were twice as likely to have opioids discontinued, and for cocaine, they were three times more likely,” said lead author Julie Gaither, PhD, RN, an instructor at Yale University School of Medicine in the pediatrics department.
More articles on opioids:
Trump urges Senate to pass bill curbing synthetic opioid shipments
Opioid epidemic does not influence unemployment levels, researchers find
Trump calls for federal suit against opioid makers, supplies
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
